NCEL.US NewcelX Ltd.
- Market cap
- USD 15.1M
- P/E
- 5.0x
- P/B
- 2.46x
- ROE
- 47.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NCEL.US undervalued?
Graham numberNCEL.US trades 25.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NewcelX Ltd. fundamental analysis
No fundamental analysis for NewcelX Ltd. yet.
NewcelX Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NewcelX Ltd.
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Ag…
Full company profileNewcelX Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NewcelX Ltd. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | - | - | -10.1K | -11.4K | -11.4K | -3.32K | - | - |
| Operating Income | -5.77M | -3.45K | -4.20M | -2.30M | -11.9M | -15.5M | -11.8M | -4.38M | -2.47M | -13.9M |
| EBITDA | -5.77M | -3.33K | -4.63M | 69.6M | -11.9M | -15.5M | -11.8M | -3.63M | -2.24M | -7.66M |
| Net Income | -6.66M | -5.15K | -5.45M | -2.86M | -11.9M | -16.5M | -12.2M | -1.98M | -8.30M | 2.89M |
| EPS | -5.65 | -322 | -4.89 | -5.94 | -8.10 | -8.38 | -3.19 | -13 | -2.16 | 0.49 |
| Balance Sheet | ||||||||||
| Total Assets | 2.29M | 146K | 696K | 1.21M | 5.76M | 9.28M | 1.85M | 2.23M | 11.4M | 9.70M |
| Total Liabilities | 10.0M | 8.96M | 6.87M | 10.2M | 5.22M | 6.00M | 10.7M | 827K | 4.20M | 3.66M |
| Shareholders' Equity | -7.72M | -8.81M | -6.17M | -8.98M | 542K | 3.28M | -8.83M | 1.41M | 7.25M | 6.04M |
| Cash & Short-term Investments | 2.18M | 6.68K | 220K | 93.7K | 5.43M | 8.95M | 898K | 1.67M | 2.20M | 710K |
| Total Debt | 8.87M | 7.09M | 842K | 2.08M | - | - | 1.63M | - | 355K | 392K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.43M | -2.73M | -190K | -729K | -14.9M | -13.9M | -9.68M | -4.27M | -2.77M | -5.75M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 4.00 | 39.6K | 640K | 4.00 | 3.92K | 8.00K | 16.00 |
| Free Cash Flow | -5.43M | -2.73M | -190K | -729K | -15.0M | -13.9M | -9.68M | -4.27M | -2.77M | -5.75M |
| Ratios | ||||||||||
| ROE | - | - | - | - | -2,202.5% | -502.8% | - | -140.8% | -114.5% | 47.9% |
| ROA | -290.9% | -3.5% | -782.2% | -236.2% | -207.2% | -177.8% | -659.1% | -88.7% | -72.5% | 29.8% |
| Debt to Equity | - | - | - | - | - | - | - | - | 0.05x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
NewcelX Ltd. dividends
NewcelX Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Oct 31, 2025.
Who owns NewcelX Ltd.
- Insiders 65.58%
- Institutions 1.27%
- Public & others 33.15%
- Shares outstanding 5.78M
- Free float 2.79M
Top funds holding NCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SFR Global Wealth Fund | 250.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding NCEL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 11.2K | 0.19% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 700.00 | 0.01% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 9.00 | 0.00% | +800.00% | Jun 2026 |
| CoreCap Advisors, LLC | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
NewcelX Ltd. company profile
- Company name
- NewcelX Ltd.
- Ticker
- NCEL.US
- ISIN
- CH1442297896
- Exchange
- USA Stocks
- Listed since
- Jan 29, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- Hohstrasse 1, Kloten, Switzerland, 8302
- Phone
- 41 44 512 21 50
- Website
- newcelx.com
About NewcelX Ltd.
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
NewcelX Ltd. management
6- Mr. Ronen Twito CPACEO & Executive Chairman · born 1975
- Prof. Michel Revel M.D., Ph.D.Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director · born 1938
- Mr. Omri HagaiChief Financial Officer · born 1986
- Mr. Alexander C. Zwyer M.B.A.Chief Business Officer & Executive Director · born 1969
- Dr. Eric Konofal M.D., Ph.D.Head of Doxa Program · born 1967
- Prof. Ariel Revel M.D.Director of Medical Affairs · born 1961